{"success":true,"data":{"pressRelease":{"id":"70140","rtpr_id":"nPn88Xgfma","ticker":"CPIX","exchange":"NASDAQ","all_tickers":["CPIX","RDHL","2RHY"],"title":"RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement","author":"PR Newswire","published_at":"2026-06-22T20:10:00.051Z","article_body":"RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement\n\nPR Newswire\n\nTEL AVIV, Israel and RALEIGH, N.C., June 22, 2026\n\n$6 million upfront with up to approximately $13.4 million of potential\naggregate gross proceeds upon the exercise in full of warrants\n\nTEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- RedHill\nBiopharma Ltd. (https://www.redhillbio.com/home/default.aspx) (NASDAQ: RDHL)\n(\"RedHill\" or the \"Company\"), a specialty biopharmaceutical company, today\nannounced the closing of its previously announced private placement for the\npurchase and sale of an aggregate of 8,571,429 American Depositary Shares\n(\"ADSs\") (or ADS equivalents in lieu thereof), each ADS representing ten\nthousand (10,000) ordinary shares of the Company, series A-1 warrants to\npurchase up to an aggregate of 8,571,429 ADSs and series A-2 warrants to\npurchase up to an aggregate of 8,571,429 ADSs, at a combined purchase price of\n$0.70 per ADS (or ADS equivalent in lieu thereof) and accompanying warrants.\nThe Series A-1 warrants have an exercise price of $0.86 per ADS, are\nexercisable immediately and have a term of five years following the\nEffectiveness Date (as defined below), and the Series A-2 warrants have an\nexercise price of $0.70 per ADS, are exercisable immediately and have a term\nof 18 months following the Effectiveness Date.\n\n \n\nThe upfront proceeds are expected to strengthen RedHill's near-term liquidity\nand support a strategic, transformative, potential acquisition of\ncommercial-stage, revenue-generating pharmaceutical product assets, which, if\ncompleted, would significantly expand the Company's commercial portfolio and\nrevenue base. No definitive acquisition agreement has been executed, and the\npotential transaction remains subject to various conditions. There can be no\nassurance that any such transaction will be completed.\n\nH.C. Wainwright & Co. acted as the exclusive placement agent for the\noffering.\n\nThe gross proceeds to the Company from this offering were approximately $6\nmillion, before deducting the placement agent's fees and other offering\nexpenses payable by the Company. The potential additional gross proceeds to\nthe Company from the series A-1 warrants and the series A-2 warrants, if fully\nexercised on a cash basis, will be approximately $13.4 million. No assurance\ncan be given that any of the series warrants will be exercised, or that the\nCompany will receive cash proceeds from the exercise of the series warrants.\n\nThe securities described above were offered in a private placement under\nSection 4(a)(2) of the Securities Act of 1933, as amended (the \"Securities\nAct\"), and/or Regulation D promulgated thereunder and, along with the ordinary\nshares of the Company represented by ADSs underlying the warrants, have not\nbeen registered under the Securities Act or applicable state securities laws.\nAccordingly, the securities issued in the private placement and ordinary\nshares of the Company represented by ADSs underlying the warrants may not be\noffered or sold in the United States except pursuant to an effective\nregistration statement or an applicable exemption from the registration\nrequirements of the Securities Act and such applicable state securities laws.\nPursuant to a registration rights agreement with the investors, the Company\nhas agreed to file a resale registration statement covering the securities\ndescribed above (such date of effectiveness of the resale registration\nstatement, the \"Effectiveness Date\").\n\nThis press release shall not constitute an offer to sell or a solicitation of\nan offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or other jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or other\njurisdiction.\n\nAbout RedHill Biopharma\n\nRedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical\ncompany primarily focused on U.S. development and commercialization of drugs\nfor gastrointestinal diseases, infectious diseases and\noncology. RedHill promotes the FDA-approved gastrointestinal\ndrug Talicia(®)(,) for the treatment of Helicobacter pylori (H.\npylori) infection in adults(([1])), with a U.S. co-commercialization\nagreement with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key\nclinical late-stage development programs include: (i) opaganib (ABC294640), a\nfirst-in-class, orally administered sphingosine kinase-2 (SPHK2) selective\ninhibitor with anti-inflammatory, antiviral, metabolic and anticancer\nactivity, targeting multiple indications with U.S. government and academic\ncollaborations intended for medical countermeasure development including for\nEbola virus disease, radiation exposure indications such as GI-Acute Radiation\nSyndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an\nongoing Phase 2 study in prostate cancer in combination with Bayer's\ndarolutamide; (ii) RHB-102 (Bekinda®), with a planned Phase 2\nproof-of-concept study for GLP-1/GIP receptor agonist-associated GI\nintolerance, positive results from a U.S. Phase 3 study for acute\ngastroenteritis and gastritis, positive results from a U.S. Phase 2 study\nfor IBS-D and potential UK submission for chemotherapy and radiotherapy\ninduced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals\n(EBR: HYL) for worldwide development and commercialization outside North\nAmerica; (iii) RHB-204, a next-generation optimized formulation of RHB-104,\nwith a planned Phase 2 study for Crohn's disease (based on RHB-104's positive\nPhase 3 Crohn's disease study results); and (iv) RHB-107 (upamostat), an\noral broad-acting, host-directed, serine protease inhibitor with potential\nfor pandemic preparedness, including COVID-19 and also targeting multiple\ncancer and inflammatory gastrointestinal diseases.\n\nMore information about the Company is available at www.redhillbio.com\n(https://www.redhillbio.com/home/default.aspx)  / X.com/RedHillBio\n(https://x.com/RedHillBio) .\n\nForward Looking Statements\n\nThis press release contains \"forward-looking statements\" within the meaning of\nthe Private Securities Litigation Reform Act of 1995 and may discuss\ninvestment opportunities, stock analysis, financial performance, investor\nrelations, and market trends. Such statements may be preceded by the words\n\"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\"\n\"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar\nwords and include, among others, the use of proceeds from the offering, the\npotential exercise of the series warrants and potential proceeds therefrom,\npotential acquisition of strategic products, statements regarding the\npotential submission of Talicia® for UK Marketing Authorisation and any\napproval thereof and statements regarding the potential effects of Talicia®\nin the treatment of Helicobacter pylori infection. Forward-looking statements\nare based on certain assumptions and are subject to various known and unknown\nrisks and uncertainties, many of which are beyond the Company's control and\ncannot be predicted or quantified, and consequently, actual results may differ\nmaterially from those expressed or implied by such forward-looking statements.\nSuch risks and uncertainties include, without limitation: market and other\nconditions, the risk that the MAA submission for Talicia may not be approved;\nthe risk that the Company will not succeed in its enforcement action against\nKukbo, and if successful may not recover all or any of awards granted by the\nNew York Supreme Court; the risk that opaganib does not receive a priority\nreview voucher, marketing exclusivity or accelerated development and review\ntimes; the risk that opaganib is not accepted into Ebola virus disease control\nprograms, or if accepted, that it does not demonstrate efficacy; the risk that\ndevelopment of RHB-204 for Crohn's disease may not be completed, or if\ncompleted may not be approved or may not achieve commercial success; the risk\nthat opaganib is not effective against the indications for which we develop\nour products; the risk that RHB-102 (Bekinda) does not effectively reduce\nGLP-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the\nCompany's ability to regain and maintain compliance with Nasdaq's listing\nrequirements, including the minimum bid price requirement; the risk that the\naddition of new revenue generating products or out-licensing transactions will\nnot occur; the risk that the Company will not receive future milestone\npayments under its existing agreements or that they will be less than\nanticipated; the risk of current uncertainty regarding U.S. government\nresearch and development funding and that the U.S. government is under no\nobligation to continue to support development of our products and can cease\nsuch support at any time; the risk that acceptance onto the RNCP Product\nDevelopment Pipeline or other governmental and non-governmental development\nprograms will not guarantee ongoing development or that any such development\nwill not be completed or successful; the risk that the FDA does not agree with\nthe Company's proposed development plans for its programs; the risk that the\nCompany's development programs and studies may not be successful and, even if\nsuccessful, such studies and results may not be sufficient for regulatory\napplications, including emergency use or marketing applications, and that\nadditional studies may be required; the risk that the Company will not\nsuccessfully commercialize its products; as well as risks and uncertainties\nassociated with (i) the initiation, timing, progress and results of the\nCompany's research, manufacturing, pre-clinical studies, clinical trials, and\nother therapeutic candidate development efforts, and the timing of the\ncommercial launch of its commercial products and ones it may acquire or\ndevelop in the future; (ii) the Company's ability to advance its therapeutic\ncandidates into clinical trials or to successfully complete its pre-clinical\nstudies or clinical trials or the development of any necessary commercial\ncompanion diagnostics; (iii) the extent and number and type of additional\nstudies that the Company may be required to conduct and the Company's receipt\nof regulatory approvals for its therapeutic candidates, and the timing of\nother regulatory filings, approvals and feedback; (iv) the manufacturing,\nclinical development, commercialization, and market acceptance of the\nCompany's therapeutic candidates and Talicia; (v) the Company's ability to\nsuccessfully commercialize and promote Talicia; (vi) the Company's ability to\nestablish and maintain corporate collaborations; (vii) the Company's ability\nto acquire products approved for marketing in the U.S. that achieve commercial\nsuccess and build its own marketing and commercialization capabilities; (viii)\nthe interpretation of the properties and characteristics of the Company's\ntherapeutic candidates and the results obtained with its therapeutic\ncandidates in research, pre-clinical studies or clinical trials; (ix) the\nimplementation of the Company's business model, strategic plans for its\nbusiness and therapeutic candidates; (x) the scope of protection the Company\nis able to establish and maintain for intellectual property rights covering\nits therapeutic candidates and its ability to operate its business without\ninfringing the intellectual property rights of others; (xi) parties from whom\nthe Company licenses its intellectual property defaulting in their obligations\nto the Company; (xii) the Company's ability to collect on its judgment against\nKukbo; (xiii) estimates of the Company's expenses, future revenues, capital\nrequirements and needs for additional financing; (xiv) the effect of patients\nsuffering adverse experiences using investigative drugs under the Company's\nExpanded Access Program; (xv) competition from other companies and\ntechnologies within the Company's industry; and (xvi) the hiring and\nemployment commencement date of executive managers. More detailed information\nabout the Company and the risk factors that may affect the realization of\nforward-looking statements is set forth in the Company's filings with the\nSecurities and Exchange Commission (SEC), including the Company's Annual\nReport on Form 20-F filed with the SEC on April 27, 2026. All forward-looking\nstatements included in this press release are made only as of the date of this\npress release. The Company assumes no obligation to update any written or oral\nforward-looking statement, whether as a result of new information, future\nevents or otherwise unless required by law.\n\nCompany contact:\n\nAdi Frish\nChief Corporate & Business Development Officer\nRedHill Biopharma\nadi@redhillbio.com (mailto:adi@redhillbio.com)\n\n[1]Talicia(®) (omeprazole magnesium, amoxicillin and rifabutin) is indicated\nfor the treatment of H. pylori infection in adults. For full prescribing\ninformation see: www.Talicia.com (https://www.talicia.com/) .\n\nLogo -\nhttps://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpg\n(https://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpg)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/redhill-biopharma-announces-closing-of-up-to-19-4-million-private-placement-302806815.html\n(https://www.prnewswire.com/news-releases/redhill-biopharma-announces-closing-of-up-to-19-4-million-private-placement-302806815.html)\n\nSOURCE RedHill Biopharma Ltd.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn88Xgfma","title":"RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement","author":"PR Newswire","ticker":"CPIX","created":"2026-06-22T20:10:00.051Z","tickers":["CPIX","RDHL","2RHY"],"exchange":"NASDAQ","article_body":"RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement\n\nPR Newswire\n\nTEL AVIV, Israel and RALEIGH, N.C., June 22, 2026\n\n$6 million upfront with up to approximately $13.4 million of potential\naggregate gross proceeds upon the exercise in full of warrants\n\nTEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- RedHill\nBiopharma Ltd. (https://www.redhillbio.com/home/default.aspx) (NASDAQ: RDHL)\n(\"RedHill\" or the \"Company\"), a specialty biopharmaceutical company, today\nannounced the closing of its previously announced private placement for the\npurchase and sale of an aggregate of 8,571,429 American Depositary Shares\n(\"ADSs\") (or ADS equivalents in lieu thereof), each ADS representing ten\nthousand (10,000) ordinary shares of the Company, series A-1 warrants to\npurchase up to an aggregate of 8,571,429 ADSs and series A-2 warrants to\npurchase up to an aggregate of 8,571,429 ADSs, at a combined purchase price of\n$0.70 per ADS (or ADS equivalent in lieu thereof) and accompanying warrants.\nThe Series A-1 warrants have an exercise price of $0.86 per ADS, are\nexercisable immediately and have a term of five years following the\nEffectiveness Date (as defined below), and the Series A-2 warrants have an\nexercise price of $0.70 per ADS, are exercisable immediately and have a term\nof 18 months following the Effectiveness Date.\n\n \n\nThe upfront proceeds are expected to strengthen RedHill's near-term liquidity\nand support a strategic, transformative, potential acquisition of\ncommercial-stage, revenue-generating pharmaceutical product assets, which, if\ncompleted, would significantly expand the Company's commercial portfolio and\nrevenue base. No definitive acquisition agreement has been executed, and the\npotential transaction remains subject to various conditions. There can be no\nassurance that any such transaction will be completed.\n\nH.C. Wainwright & Co. acted as the exclusive placement agent for the\noffering.\n\nThe gross proceeds to the Company from this offering were approximately $6\nmillion, before deducting the placement agent's fees and other offering\nexpenses payable by the Company. The potential additional gross proceeds to\nthe Company from the series A-1 warrants and the series A-2 warrants, if fully\nexercised on a cash basis, will be approximately $13.4 million. No assurance\ncan be given that any of the series warrants will be exercised, or that the\nCompany will receive cash proceeds from the exercise of the series warrants.\n\nThe securities described above were offered in a private placement under\nSection 4(a)(2) of the Securities Act of 1933, as amended (the \"Securities\nAct\"), and/or Regulation D promulgated thereunder and, along with the ordinary\nshares of the Company represented by ADSs underlying the warrants, have not\nbeen registered under the Securities Act or applicable state securities laws.\nAccordingly, the securities issued in the private placement and ordinary\nshares of the Company represented by ADSs underlying the warrants may not be\noffered or sold in the United States except pursuant to an effective\nregistration statement or an applicable exemption from the registration\nrequirements of the Securities Act and such applicable state securities laws.\nPursuant to a registration rights agreement with the investors, the Company\nhas agreed to file a resale registration statement covering the securities\ndescribed above (such date of effectiveness of the resale registration\nstatement, the \"Effectiveness Date\").\n\nThis press release shall not constitute an offer to sell or a solicitation of\nan offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or other jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or other\njurisdiction.\n\nAbout RedHill Biopharma\n\nRedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical\ncompany primarily focused on U.S. development and commercialization of drugs\nfor gastrointestinal diseases, infectious diseases and\noncology. RedHill promotes the FDA-approved gastrointestinal\ndrug Talicia(®)(,) for the treatment of Helicobacter pylori (H.\npylori) infection in adults(([1])), with a U.S. co-commercialization\nagreement with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key\nclinical late-stage development programs include: (i) opaganib (ABC294640), a\nfirst-in-class, orally administered sphingosine kinase-2 (SPHK2) selective\ninhibitor with anti-inflammatory, antiviral, metabolic and anticancer\nactivity, targeting multiple indications with U.S. government and academic\ncollaborations intended for medical countermeasure development including for\nEbola virus disease, radiation exposure indications such as GI-Acute Radiation\nSyndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an\nongoing Phase 2 study in prostate cancer in combination with Bayer's\ndarolutamide; (ii) RHB-102 (Bekinda®), with a planned Phase 2\nproof-of-concept study for GLP-1/GIP receptor agonist-associated GI\nintolerance, positive results from a U.S. Phase 3 study for acute\ngastroenteritis and gastritis, positive results from a U.S. Phase 2 study\nfor IBS-D and potential UK submission for chemotherapy and radiotherapy\ninduced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals\n(EBR: HYL) for worldwide development and commercialization outside North\nAmerica; (iii) RHB-204, a next-generation optimized formulation of RHB-104,\nwith a planned Phase 2 study for Crohn's disease (based on RHB-104's positive\nPhase 3 Crohn's disease study results); and (iv) RHB-107 (upamostat), an\noral broad-acting, host-directed, serine protease inhibitor with potential\nfor pandemic preparedness, including COVID-19 and also targeting multiple\ncancer and inflammatory gastrointestinal diseases.\n\nMore information about the Company is available at www.redhillbio.com\n(https://www.redhillbio.com/home/default.aspx)  / X.com/RedHillBio\n(https://x.com/RedHillBio) .\n\nForward Looking Statements\n\nThis press release contains \"forward-looking statements\" within the meaning of\nthe Private Securities Litigation Reform Act of 1995 and may discuss\ninvestment opportunities, stock analysis, financial performance, investor\nrelations, and market trends. Such statements may be preceded by the words\n\"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\"\n\"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar\nwords and include, among others, the use of proceeds from the offering, the\npotential exercise of the series warrants and potential proceeds therefrom,\npotential acquisition of strategic products, statements regarding the\npotential submission of Talicia® for UK Marketing Authorisation and any\napproval thereof and statements regarding the potential effects of Talicia®\nin the treatment of Helicobacter pylori infection. Forward-looking statements\nare based on certain assumptions and are subject to various known and unknown\nrisks and uncertainties, many of which are beyond the Company's control and\ncannot be predicted or quantified, and consequently, actual results may differ\nmaterially from those expressed or implied by such forward-looking statements.\nSuch risks and uncertainties include, without limitation: market and other\nconditions, the risk that the MAA submission for Talicia may not be approved;\nthe risk that the Company will not succeed in its enforcement action against\nKukbo, and if successful may not recover all or any of awards granted by the\nNew York Supreme Court; the risk that opaganib does not receive a priority\nreview voucher, marketing exclusivity or accelerated development and review\ntimes; the risk that opaganib is not accepted into Ebola virus disease control\nprograms, or if accepted, that it does not demonstrate efficacy; the risk that\ndevelopment of RHB-204 for Crohn's disease may not be completed, or if\ncompleted may not be approved or may not achieve commercial success; the risk\nthat opaganib is not effective against the indications for which we develop\nour products; the risk that RHB-102 (Bekinda) does not effectively reduce\nGLP-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the\nCompany's ability to regain and maintain compliance with Nasdaq's listing\nrequirements, including the minimum bid price requirement; the risk that the\naddition of new revenue generating products or out-licensing transactions will\nnot occur; the risk that the Company will not receive future milestone\npayments under its existing agreements or that they will be less than\nanticipated; the risk of current uncertainty regarding U.S. government\nresearch and development funding and that the U.S. government is under no\nobligation to continue to support development of our products and can cease\nsuch support at any time; the risk that acceptance onto the RNCP Product\nDevelopment Pipeline or other governmental and non-governmental development\nprograms will not guarantee ongoing development or that any such development\nwill not be completed or successful; the risk that the FDA does not agree with\nthe Company's proposed development plans for its programs; the risk that the\nCompany's development programs and studies may not be successful and, even if\nsuccessful, such studies and results may not be sufficient for regulatory\napplications, including emergency use or marketing applications, and that\nadditional studies may be required; the risk that the Company will not\nsuccessfully commercialize its products; as well as risks and uncertainties\nassociated with (i) the initiation, timing, progress and results of the\nCompany's research, manufacturing, pre-clinical studies, clinical trials, and\nother therapeutic candidate development efforts, and the timing of the\ncommercial launch of its commercial products and ones it may acquire or\ndevelop in the future; (ii) the Company's ability to advance its therapeutic\ncandidates into clinical trials or to successfully complete its pre-clinical\nstudies or clinical trials or the development of any necessary commercial\ncompanion diagnostics; (iii) the extent and number and type of additional\nstudies that the Company may be required to conduct and the Company's receipt\nof regulatory approvals for its therapeutic candidates, and the timing of\nother regulatory filings, approvals and feedback; (iv) the manufacturing,\nclinical development, commercialization, and market acceptance of the\nCompany's therapeutic candidates and Talicia; (v) the Company's ability to\nsuccessfully commercialize and promote Talicia; (vi) the Company's ability to\nestablish and maintain corporate collaborations; (vii) the Company's ability\nto acquire products approved for marketing in the U.S. that achieve commercial\nsuccess and build its own marketing and commercialization capabilities; (viii)\nthe interpretation of the properties and characteristics of the Company's\ntherapeutic candidates and the results obtained with its therapeutic\ncandidates in research, pre-clinical studies or clinical trials; (ix) the\nimplementation of the Company's business model, strategic plans for its\nbusiness and therapeutic candidates; (x) the scope of protection the Company\nis able to establish and maintain for intellectual property rights covering\nits therapeutic candidates and its ability to operate its business without\ninfringing the intellectual property rights of others; (xi) parties from whom\nthe Company licenses its intellectual property defaulting in their obligations\nto the Company; (xii) the Company's ability to collect on its judgment against\nKukbo; (xiii) estimates of the Company's expenses, future revenues, capital\nrequirements and needs for additional financing; (xiv) the effect of patients\nsuffering adverse experiences using investigative drugs under the Company's\nExpanded Access Program; (xv) competition from other companies and\ntechnologies within the Company's industry; and (xvi) the hiring and\nemployment commencement date of executive managers. More detailed information\nabout the Company and the risk factors that may affect the realization of\nforward-looking statements is set forth in the Company's filings with the\nSecurities and Exchange Commission (SEC), including the Company's Annual\nReport on Form 20-F filed with the SEC on April 27, 2026. All forward-looking\nstatements included in this press release are made only as of the date of this\npress release. The Company assumes no obligation to update any written or oral\nforward-looking statement, whether as a result of new information, future\nevents or otherwise unless required by law.\n\nCompany contact:\n\nAdi Frish\nChief Corporate & Business Development Officer\nRedHill Biopharma\nadi@redhillbio.com (mailto:adi@redhillbio.com)\n\n[1]Talicia(®) (omeprazole magnesium, amoxicillin and rifabutin) is indicated\nfor the treatment of H. pylori infection in adults. For full prescribing\ninformation see: www.Talicia.com (https://www.talicia.com/) .\n\nLogo -\nhttps://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpg\n(https://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpg)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/redhill-biopharma-announces-closing-of-up-to-19-4-million-private-placement-302806815.html\n(https://www.prnewswire.com/news-releases/redhill-biopharma-announces-closing-of-up-to-19-4-million-private-placement-302806815.html)\n\nSOURCE RedHill Biopharma Ltd.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/1334141/5268648/RedHill_Biopharma_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-22T20:10:00.104644185Z","server_sent_at_ms":1782159000104},"received_at":"2026-06-22T20:10:00.255Z","source_url":"https://www.prnewswire.com/news-releases/redhill-biopharma-announces-closing-of-up-to-19-4-million-private-placement-302806815.html"},"analysis":{"id":"59539","press_release_id":"70140","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"RedHill Biopharma, a co-commercialization partner of Cumberland Pharmaceuticals for the drug Talicia, closed a private placement raising $6 million in upfront proceeds.\n\nThe offering consisted of 8,571,429 ADSs priced at $0.70, with warrants that could generate an additional $13.4 million if exercised in full.\n\nRedHill intends to use the funds to strengthen liquidity and pursue potential acquisitions of commercial-stage assets.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Partner RedHill closes $6M private placement; neutral direct impact on CPIX."},"keyFigures":{"dealValueUsd":"$6 million","offeringPrice":0.7,"sharesOffered":8571429,"customDimensions":{"total_potential_proceeds":"$19.4 million","potential_warrant_proceeds":"$13.4 million","series_a1_warrant_exercise_price":"$0.86","series_a2_warrant_exercise_price":"$0.70"}},"quotedText":"The upfront proceeds are expected to strengthen RedHill's near-term liquidity and support a strategic, transformative, potential acquisition of commercial-stage, revenue-generating pharmaceutical product assets","namedEntities":{"people":[],"products":["Talicia"],"companies":[{"name":"RedHill Biopharma Ltd.","ticker":"RDHL","relationship":"partner"},{"name":"H.C. Wainwright & Co.","relationship":"placement agent"},{"name":"Cumberland Pharmaceuticals","ticker":"CPIX","relationship":"partner"}],"dollarAmounts":[{"amount":"$19.4 million","context":"potential aggregate gross proceeds"},{"amount":"$6 million","context":"upfront gross proceeds"},{"amount":"$13.4 million","context":"potential gross proceeds from warrants"},{"amount":"$0.70","context":"combined purchase price per ADS"},{"amount":"$0.86","context":"Series A-1 warrant exercise price"}]},"materialImpact":{"score":1,"reasoning":"The press release details a private placement financing by RedHill Biopharma (RDHL), a partner of the filer Cumberland Pharmaceuticals (CPIX). There is no stated direct financial or operational impact on CPIX resulting from this transaction."},"tickerRelevance":{"others":[{"ticker":"RDHL","relevance":"partner"}],"primary":"CPIX"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"partner-financing","issuerAuthored":false}},"event_type":"offering","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"RedHill Biopharma, a co-commercialization partner of Cumberland Pharmaceuticals for the drug Talicia, closed a private placement raising $6 million in upfront proceeds.\n\nThe offering consisted of 8,571,429 ADSs priced at $0.70, with warrants that could generate an additional $13.4 million if exercised in full.\n\nRedHill intends to use the funds to strengthen liquidity and pursue potential acquisitions of commercial-stage assets.","key_figures":{"dealValueUsd":"$6 million","offeringPrice":0.7,"sharesOffered":8571429,"customDimensions":{"total_potential_proceeds":"$19.4 million","potential_warrant_proceeds":"$13.4 million","series_a1_warrant_exercise_price":"$0.86","series_a2_warrant_exercise_price":"$0.70"}},"named_entities":{"people":[],"products":["Talicia"],"companies":[{"name":"RedHill Biopharma Ltd.","ticker":"RDHL","relationship":"partner"},{"name":"H.C. Wainwright & Co.","relationship":"placement agent"},{"name":"Cumberland Pharmaceuticals","ticker":"CPIX","relationship":"partner"}],"dollarAmounts":[{"amount":"$19.4 million","context":"potential aggregate gross proceeds"},{"amount":"$6 million","context":"upfront gross proceeds"},{"amount":"$13.4 million","context":"potential gross proceeds from warrants"},{"amount":"$0.70","context":"combined purchase price per ADS"},{"amount":"$0.86","context":"Series A-1 warrant exercise price"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-22T20:14:36.043Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"partner-financing","issuerAuthored":false}},"durationMs":160126,"modelName":"george-droid-qwen-72b"}}